Conversation with The Cancer LetterCOVID-19 & CancerFree Curigliano: “I don’t want to see more people dying”As COVID-19 deaths rise in Italy, oncologists hope to see the curve flatten March 20, 2020Vol.46 No.12By Alexandria Carolan
Conversation with The Cancer LetterCOVID-19 & CancerFree Nelson: How Hopkins is managing COVID-19 pandemic March 16, 2020Vol.46 No.12By Paul Goldberg
Conversation with The Cancer LetterCOVID-19 & CancerFree Is your cancer center ready for COVID-19? March 13, 2020Vol.46 No.11By Alexandria Carolan
Conversation with The Cancer LetterCOVID-19 & CancerFree What to expect: Oncology’s response to coronavirus in Italy"It's like being in a war" March 11, 2020Vol.46 No.11By Alexandria Carolan
Conversation with The Cancer Letter NCI’s Penberthy: We may be seeing some impact of treatment in lung cancer mortality, but we need more data February 07, 2020Vol.46 No.06By Matthew Bin Han Ong
Conversation with The Cancer Letter ACS’s Siegel: Large drop in lung cancer mortality likely driven by treatment, not just drugs February 07, 2020Vol.46 No.06By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Thomas Lynch lists his areas of emphasis at the Hutch:Solid tumors, immuno-oncology, big data, microbial involvement January 31, 2020Vol.46 No.5By Paul Goldberg
Conversation with The Cancer Letter Attorney: Moffitt has made a “very irresponsible decision”—Thomas Sellers “never was a participant” in China’s Thousand Talents Program January 24, 2020Vol.46 No.04By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Robert Winn holds forth on big data, bench-to-community research—and being the only African American director of an NCI-designated cancer center January 17, 2020Vol.46 No.03By Paul Goldberg
Conversation with The Cancer LetterFreeReal-world Evidence Learning to harmonize: Ten health care research organizations tell us how they formulated common definitions for real-world endpoints November 22, 2019Vol.45 No.44By Matthew Bin Han Ong
